IF 122.7 1区医学

Allergy Pub Date : 2024-06-18 DOI: 10.1038/s41573-024-00958-9

Terry Kenakin

{"title":"Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition","authors":"Terry Kenakin","doi":"10.1038/s41573-024-00958-9","DOIUrl":"10.1038/s41573-024-00958-9","url":null,"abstract":"Despite advances in chemical, computational and biological sciences, the rate of attrition of drug candidates in clinical development is still high. A key point in the small-molecule discovery process that could provide opportunities to help address this challenge is the pharmacological characterization of hit and lead compounds, culminating in the selection of a drug candidate. Deeper characterization is increasingly important, because the ‘quality’ of drug efficacy, at least for G protein-coupled receptors (GPCRs), is now understood to be much more than activation of commonly evaluated pathways such as cAMP signalling, with many more ‘efficacies’ of ligands that could be harnessed therapeutically. Such characterization is being enabled by novel assays to characterize the complex behaviour of GPCRs, such as biased signalling and allosteric modulation, as well as advances in structural biology, such as cryo-electron microscopy. This article discusses key factors in the assessments of the pharmacology of hit and lead compounds in the context of GPCRs as a target class, highlighting opportunities to identify drug candidates with the potential to address limitations of current therapies and to improve the probability of them succeeding in clinical development. Deeper pharmacological characterization of hit and lead compounds is being enabled by novel assays to characterize target behaviour as well as by advances in structural biology. This article discusses key factors in pharmacological characterization in the context of G protein-coupled receptors as a target class, highlighting opportunities to identify drug candidates with the potential to address limitations of current therapies and to increase the probability of them succeeding in clinical trials.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 8","pages":"626-644"},"PeriodicalIF":122.7,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines 作者更正：二级药理学的最新进展及其对新药安全性的影响。

IF 122.7 1区医学

Allergy Pub Date : 2024-06-17 DOI: 10.1038/s41573-024-00993-6

Richard J. Brennan, Stephen Jenkinson, Andrew Brown, Annie Delaunois, Bérengère Dumotier, Malar Pannirselvam, Mohan Rao, Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, Yoav Timsit, Vicencia Toledo Sales, Duncan Armstrong, Armando Lagrutta, Scott W. Mittlestadt, Russell Naven, Ravikumar Peri, Sonia Roberts, James M. Vergis, Jean-Pierre Valentin